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We used high-resolution array analysis to discover a recurrent lung
cancer amplicon located at 14q13.3. Low-level gain of this region
was detected in 15% of lung cancer samples, and high-level
amplification was detected in an additional 4% of samples. High-
level focal amplification appears to be specific to lung cancers,
because it was not detected in>500 samples of other tumor types.
Mapping of the commonly amplified region revealed there are
three genes in the core region, all of which encode transcription
factors with either established lung developmental function (TTF1/
NKX2-1,NKX2-8) or potential lung developmental function (PAX9).
All three genes were overexpressed to varying degrees in ampli-
fied samples, although TTF1/NKX2-1 was not expressed in the
squamous cancer subtype, consistent with previous reports. Re-
markably, overexpression of any pairwise combination of these
genes showed pronounced synergy in promoting the proliferation
of immortalized human lung epithelial cells. Analysis of human
lung cancer cell lines by both RNAi and ectopic overexpression
further substantiates an oncogenic role for these transcription
factors. These results, taken together with previous reports of
oncogenic alterations of transcription factors involved in lung
development (p63, CEBPA), suggest genetic alterations that di-
rectly interfere with transcriptional networks normally regulating
lung development may be a more common feature of lung cancer
than previously realized.
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Many of the major genetic alterations that drive the devel-opment of human carcinomas involve transcription fac-
tors. The SMAD4 gene is frequently mutated in pancreatic and
colon cancer, thereby blocking the ability of TGF- to inhibit
epithelial cell growth. SMAD4 encodes the common transcrip-
tion coactivator of the five different Smad factors that are
regulated by the TGF family of receptors. Mutational activation
of the Wnt pathway protein -catenin occurs often in colon and
hepatocellular carcinomas, leading to its direct activation of TCF
transcription factors and increased expression of Wnt target
genes. Gene amplification at 8q24 and resultant increased
expression of MYC is a common occurrence in carcinomas,
leading to the increased formation of Myc:Max heterodimer
transcription factors that alter gene expression in large part by
recruiting histone-modifying enzymes. p53 is the most widely
mutated gene in all carcinomas and encodes a transcription
factor that responds to DNA damage and a wide variety of other
stress signals and alters the expression of several key mediators
of cell cycle progression, apoptosis, and senescence.
Less commonly documented in carcinomas are genetic alter-
ations of transcription factors that play tissue-specific develop-
mental roles. However, in lung cancer, there are a few examples
of cancer-associated genetic or epigenetic alteration of lung
developmental transcription factors. The first is p63, a p53
homologue at 3q27, which is required for formation of lung basal
epithelial cells (1, 2). Cancer-associated gene amplification,
which is common in squamous lung carcinomas, produces a p40
splice variant with oncogenic activity (3). The second example is
CEBPA, a transcription factor that, when knocked out, causes
abnormal proliferation of type II alveolar cells in the lung and
is silenced by promoter hypermethylation in 50% of lung
tumors (4, 5). Reintroduction of its expression suppresses the
growth of lung cancer cell lines (6). The final example is the
transcription factor encoded by N-MYC, which is frequently
amplified in small-cell lung cancer (SCLC) (7, 8), when partially
deleted disrupts branching morphogenesis (9–11), and is re-
quired for the proliferation of peripheral progenitor cells (12).
Here we report on the frequent alteration by gene amplifica-
tion in lung cancer of a locus containing the genes for three lung
developmental transcription factors and in addition demonstrate
oncogenic activity of these genes. Together with the previous
reports reviewed above, these results suggest that disruption of
lung developmental pathways could be a common characteristic
of lung cancer development.
Results
14q13.3 Amplicon Is One of the Most Frequent High-Amplitude Focal
Amplicons in Human Lung Cancer. We used ROMA, a high-
resolution array comparative genomic hybridization (CGH)
method (13), to profile the DNA copy number alterations of 77
human cancer cell lines and 184 primary human lung tumors.
Supporting information (SI) Table 2 summarizes the overall
histological classification of all samples. SI Tables 3 and 4
describe individual samples of cancer cell lines and tumors,
respectively. Microarray measurements were converted to copy
number estimates by using a segmentation algorithm based on
Kolmogorov–Smirnov statistics (14). To restrict subsequent
analysis to cancer-associated somatic genetic events, we used an
automated procedure to mask common germ-line copy number
variations (14). Next, we used an automated method, similar to
the minimal common region method developed by Tonon et al.
(15), to detect high-level focal amplicons (segmented DNA copy
number 1.5 and 5 Mb) and determined their frequency and
region of common overlap (see Materials and Methods). Of the
12 most-frequent focal amplicons, nine contained known onco-
genes that are very likely to be the driver gene, and three
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amplicons did not associate with apparent driver genes (Table 1).
The 8p12 amplicon contained FGFR1, although Tonon et al. (15)
provided evidence thatWHSC1L1 was the more likely candidate
driver gene in lung cancer. Importantly, five of the five onco-
genes that have been considered to be the best-established
oncogenes in lung cancer [MYC, KRAS, EGFR, CCND1, and
LMYC; reviewed by Minna et al. (8)] were found among the top
12 amplicons (Table 1). Thus it seems likely that the three
recurring amplicons without apparent driver genes contain
oncogenes important for lung cancer development. These three
amplicons, located at 14q13.3, 5p15.33, and 8p11.21, contained
between 5 and 11 known genes. We chose to pursue the 14q13.3
amplicon for further analysis, based on its smaller size, lowest
gene content, and status as the second most-frequent high-
amplitude amplicon (Table 1).
The 14q13.3 Amplicon Contains Three Transcription Factor Genes.
Gain of 14q13.3 was found in 19% of all samples, and high-level
amplification of 14q13.3 was found in 4% of total samples,
including three lung cancer cell lines and eight lung tumors. To
visualize the common area of overlap, we plotted the segmented
DNA copy number across a 10-Mb region that spanned the
14q13.3 amplicon for each of the highly amplified samples. Each
of the individual amplicon structures was different, but two
samples (647 and H661) were particularly informative, in that
they defined the left and right boundaries of the 480- to 530-kb
core amplified region segment shared by all 11 samples (Fig. 1A).
The size range of 480–530 kb results from the uncertainty
created by gaps in consecutive genome positions of the oligo-
nucleotides on the array. To more precisely map the boundaries
of the amplicons in the two informative samples, we used
real-time quantitative PCR (QPCR) to measure DNA copy
number at 15- to 20-kb intervals throughout the two 35-Mb
boundary regions (Fig. 1 B and C). This analysis refined the
boundaries of the commonly amplified core to a 413-kb region
containing four protein-coding genes. Three genes, TTF1,
NKX2-8, and PAX9, are fully contained within this region and
thus are candidate driver genes of 14q13.3 amplification. The
fourth gene, SLC25A21, is not a viable candidate, because the
common amplified region contains only sequences downstream
of its fourth exon.
In addition to these validated genes, there are four University
of California, Santa Cruz, gene predictions within the common
amplified region that correspond to EST sequences BX161496,
AY102071, BC042093, and BC129834. None of these four
candidate genes are predicted to contain coding sequences, nor
do they have predicted protein orthologs in six other species,
unlike the three validated genes that each clearly defined
orthologs in three or more of the six species (http://
genome.ucsc.edu). To explore the possibility these four pre-
dicted genes may possess oncogenic function but in a noncoding
capacity, we examined expression of these four predicted genes
by reverse transcriptase-dependent QPCR in a panel of RNA
isolated from five normal lung tissues, 20 lung adenocarcinomas
(AC), and 20 lung squamous-cell carcinomas (SCC) (which
included six amplified tumors). None of the four predicted genes
were expressed in any of these samples, effectively ruling out this
last possibility for their candidacy as driver oncogenes (data not
shown).
The genes TTF1 (also known as NKX2-1 or TITF1 for thyroid
transcription factor 1) and NKX2-8 (NK2 transcription factor
related locus 8) belong to the same NK2 homeodomain-
containing transcription factor gene family (16). PAX9 is a
member of the ‘‘paired box’’ (PAX)-containing transcription
factor family in which the homeodomain is also present in most
family members. However, PAX9 lacks the homeodomain but
retains the PAX DNA-binding domain (17).
Correlation of DNA Copy Number and RNA Expression of TTF1, NKX2-8,
and PAX9. A basic premise of gene amplification as a mutational
mechanism relevant to cancer is that the gene copy number gain
leads to an increased dosage of messenger RNA and protein
(18). To determine the impact of DNA copy number on RNA
expression of candidate driver genes, we profiled global RNA
expression of six amplified AC and 11 nonamplified lung tumors
by using expression arrays. This study led to the detection of
positive correlations of DNA copy number and RNA expression
of TTF1 (0.067, P 0.02),NKX2-8 (0.431, P 0.003), and PAX9
(0.101, P  0.01), demonstrating an influence of DNA copy
number on RNA expression of all three genes (SI Fig. 4). Next,
we determined by real-time QPCR the expression of these three
genes as well as 14q13.13 DNA copy number in an independent
set of 50 lung AC tumors. Using 3-fold DNA copy number
increase as the cutoff, five AC samples (10%) were found to be
amplified for the 14q13.3 region.NKX2-8was up-regulated in the
range of 4- to 15-fold in all five amplified samples (SI Fig. 5A).














5.7 36 8q24.21 1.32 3 MYC
4.2 19 14q13.3 0.53 5 Unknown
3.8 18 12p12.1 2.86 12 KRAS
3.4 20 7p11.2 0.82 3 EGFR
3.1 13 11q13.3 0.54 6 CCND1
2.7 9 1p34.2 0.59 10 LMYC
2.3 25 1q21.2 1.15 36 MCL1
2.3 33 5p15.33 0.72 11 Unknown
2.3 9 8p12 0.59 14 FGFR1
2.3 12 8p11.21 0.80 9 Unknown
1.5 7 2p24.3 0.44 2 NMYC
1.5 10 12q15 1.57 13 MDM2
High-level amplification frequency was determined by using a cutoff of segmented DNA copy number1.5. The frequency of both
chromosomal gains and amplification was determined by using a less-stringent cutoff of 1.2. The amplicon locations are based on the
March 2006 (hg18) human genome assembly (http://genome.ucsc.edu). The size of the amplicon represents the size of the minimal
overlapping region (see Materials andMethods). The genes within the amplicon include all genes from the RefSeq set that are partially
or fully contained within its boundaries. The likely driver gene, if present, denotes the commonly accepted driver gene for the previously
described amplicon.
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Clearly, NKX2-8 is a leading candidate driver gene based on its
strong correlation of RNA expression and DNA copy number
(Pearson correlation coefficient of 0.692, P 0.0001). However,
we could not rule out the driver gene candidacies of PAX9 or
TTF1, because both genes also showed positive, albeit weaker,
correlations of RNA expression and DNA copy number (Pear-
son correlation coefficients of 0.343 and 0.241, respectively, with
P values  0.001). Therefore, functional analysis of the three
candidate driver genes was essential for identification of the
driver gene(s).
Gain-of-Function Studies of TTF1, NKX2-8, and PAX9. To test the
functional consequences of enforced overexpression of candi-
date driver genes, we tested whether overexpression of any of the
candidate driver genes enhanced the tumorigenicity of lung
cancer cell lines. We used two lung cancer cell lines, one with the
14q13.3 gain (NCI-H2170, referred to as ‘‘H2170’’ hereafter) and
the other without the 14q13.3 amplicon (HCC15). Both of these
non-SCLC cancer cell lines are of the SCC subtype. To create
stable transfectants, we used retrovirus-mediated gene transfer
to enforce expression of individual genes. Overexpression of
transfected genes was confirmed by reverse transcriptase-
dependent QPCR (data not shown). None of the three candidate
genes when overexpressed further enhanced tumor formation of
amplified H2170 cells. On the contrary, in nonamplified HCC15
cells, overexpression of either TTF1 or NKX2-8 (but not PAX9)
enhanced tumorigenicity by increasing tumor take rate and
tumor size (SI Fig. 6), indicating oncogenic function for both
TTF1 and NKX2-8 in HCC15 cells. In addition, the observation
that the prooncogenic activities of TTF1 and NKX2-8 were
manifested only in nonamplified HCC15 cells suggests that
functional advantage of increased gene dosages of TTF1 or
NKX2-8 may have already been maximized in the amplified
H2170 cells.
To explore the effects of these three genes on premalignant
lung epithelial cells, we performed experiments with normal
human lung epithelial cells immortalized by SV40 large T
antigen, i.e., BEAS-2B cells (19). Individual and pairwise com-
binations of the three candidate driver genes were retrovirally
transduced into BEAS-2B cells. We found that, when plated at
low densities, BEAS-2B cells expressing individual candidate
genes did not form colonies differently from empty vector
controls (Fig. 2A). However, all three pairwise combinations
(i.e., double transfectants) formed much larger colonies, ranked
in the order of TTF1-NKX2-83 TTF1-PAX93 NKX2-8-PAX9
by visual inspection (Fig. 2A). To quantify the increased colony
sizes, the crystal violet in the stained plates was eluted in a 0.1%
SDS solution, and the absorbance at 595 nm was measured (20).
Consistent with visual inspection, each of the three pairwise
combinations showed 4- to 6-fold higher growth than all of the
single-transfectant and double-vector control transfectant cells
(Fig. 2B). To validate this synergistic growth effect, we repeated
the experiment by using different vectors that contained differ-
ent antibiotic selection marker genes (see Materials and Meth-
ods). With this second system, we were able to construct triple
transfectants overexpressing all three genes. Significant en-
hancement of colony growth was detected at a level similar to
what was observed with the double transfectants (SI Fig. 7),
suggesting that the maximal synergy was reached in the double
transfectants. These results confirmed that there is a growth-
promoting synergy among the three genes in the background of
premalignant lung epithelia.
Loss-of-Function Studies of TTF1, NKX2-8, and PAX9. The 14q13.3
amplicon does not appear to be limited to a specific subtype of
lung cancer. This is particularly intriguing in that Ttf1 protein is
rarely detected in the SCC type of lung cancer based on multiple
studies in the literature (21–24). Consistent with the literature,
in multiple squamous lung cancer cell lines (including the
amplified H2170 cells), we have not been able to detect the
protein expression of TTF1 by using a highly specific monoclonal
antibody [clone 8G7G3/1 (25)] (Fig. 3A). Notably, the RNA
message of TTF1 was undetectable in H2170 by reverse tran-
scriptase-dependent QPCR, suggesting gene silencing at the
transcription level (data not shown). Thus, TTF1 is ruled out as
a driver gene in the amplified H2170 cells. However, that
enforced expression of TTF1 enhanced the tumorigenicity of an
amplification-free SCC cells (HCC15) implies that TTF1 has
oncogenic activity and SCC cells have the physiological context
needed to manifest the oncogenic activity of TTF1.
Because amplified SCC cells such as H2170 present a simpli-
fied case in which TTF1 is functionally irrelevant because of its
lack of protein expression, we wished to use this cell system to
address whether continued overexpression of the other two
candidate driver genes play a tumor maintenance role. We
screened small-hairpin RNA (shRNA) clones to identify the
effective ones that could knock down the endogenous protein
expression of NKX2-8 or PAX9 in H2170 cells. Preexisting
anti-NKX2-8 shRNA clones were obtained from Open Biosys-
tems (Huntsville, AL) (26), and the shRNA inserts were trans-
Fig. 1. The commonly amplified core region of lung cancer 14q13.3 ampli-
cons. (A) The segmented array CGH DNA copy number values (y axis) for 11
samples containing the 14q13.3 amplicon are plotted against the chromo-
some 14 nucleotide position (x axis) from the March 2006 (hg18) assembly of
the International Human Genome Sequencing Consortium (http://genome.uc-
sc.edu). The commonly amplified core region (chr14:35,820,860-36,348,636),
which maximally spans a 530-kb region, is shaded in blue. The 11 amplified
samples consist of eight primary tumors (700, 457, 1242, 1041, 817, 1308, 531,
and 647) and three cell lines (NCI-H661, NCI-H2170, and NCI-H146). NCI-H661
is from a large-cell carcinoma, both NCI-H2170 and 647 are from SCC, NCI-H146
is from an SCLC, and the remaining samples are from AC. (B and C) Determi-
nation by real-time PCR of the centromeric boundary of the amplicon found
in primary tumor sample 647 (B) and of the telomeric boundary of the
amplicon found in large-cell carcinoma cell line NCI-H661 (C). The DNA copy
numbers measured by both array CGH and real-time PCR are as plotted. This
analysis defined the two boundaries (chr14:35,897,833-36,311,043) of the
commonly amplified 413-kb region.











ferred into a RNA polymerase II-based retroviral expression
vector (pMLP) that has been shown to consistently induce high
suppression of target genes (27). With PAX9, we used the
BIOPREDsi webtool (28) and identified three top RNAi sites in
the ORF. These three sites were then specifically targeted by
using the RNAi Codex webtool (29) to generate 101-mer oligo-
nucleotides that we then cloned into the pMLP vector. After
retroviral infection and drug selection to eliminate uninfected
H2170 host cells, immunoblotting analysis of cell extracts of
stable transfectants identified one anti-NKX2-8 (N2-shRNA;
Fig. 3B) and two anti-PAX9 shRNAs (P1- and P2-shRNA; Fig.
3D) as the most potent in suppressing endogenous target protein
expression. As judged by scanning densitometry, N2-shRNA
conferred nearly 85% reduction of Nkx2-8 protein expression
(relative to the empty vector control), and both P1- and P2-
shRNA reduced the endogenous Pax9 protein expression to
7% of empty-vector control transfectants (Fig. 3 B and D).
Each population of stable H2170 shRNA transfectants was
evaluated for tumorigenicity, and we found that knocking down
NKX2-8 or PAX9 severely compromised the tumorigenicity of
H2170 cells. In the case of NKX2-8, the effective N2-shRNA
reduced the tumor take rate to only one of five mice, and in the
one mouse-forming tumor, the tumor was much smaller (Fig.
3C). With PAX9, the two effective shRNAs also resulted in
significantly reduced tumor formation (Fig. 3E). We believe it is
unlikely that nonspecific effects of the shRNAs caused the
inhibition of tumor formation. First, the degree of tumorigenic-
ity reduction correlates with the severity of knockdowns, with the
most effective shRNAs (N2-, P1-, or P2-shRNA) giving the
strongest suppression of tumor formation and take rate, whereas
other less-effective shRNAs showed milder effects on tumori-
genicity. Second, we have assessed the impact of the effective
NKX2-8 shRNA (N2-shRNA) in a nonamplified SCC cell line
(HCC15). We found that N2-shRNA did not influence the
tumorigenicity of HCC15 as it did with H2170 (data not shown),
indicating that (i) this shRNA does not have a generalized
deleterious off-target effect, and (ii) only a subset of lung cancer
cell lines depend on maintaining high levels of NKX2-8 expres-
sion. In sum, our studies suggest that both NKX2-8 and PAX9
play a pivotal role in the tumor maintenance of SCC cell with the
14q13.3 amplification.
Association of Focal 14q13.3 Amplicons with Disease Progression. In
an independent genomic DNA copy number data set consisting
of 91 clinically annotated lung AC profiled by Agilent’s (Austin,
TX) 44K platform (a full description of the data set is to be
published elsewhere), 17 samples (16%) within this data set were
found to harbor focal amplification (5 Mb) of 14q13.3 con-
taining the three candidate driver genes (SI Table 5 summarizes
the associated clinical and molecular parameters). Eight of these
17 samples (8.8% overall frequency) were considered highly
amplified (log2 of segmented DNA copy number 0.8). In
addition to these 17 samples with focal amplification, 12 other
samples contained low-level wide gain at 14q13 (SI Table 5). We
analyzed the data set for potential correlations of the 14q13.3
amplicon status with the 17 clinical parameters by Spearman
rank order correlation calculations and Fisher’s exact tests. By
stratifying the samples into two groups [early-stage lung cancer
(stages I and II) vs. late stage (stage III cancers)], a significant
positive correlation was observed between focal amplification of
14q13.3 and late-stage cancer (SI Table 6). Also, focal amplifi-
cation of 14q13.3 correlates with recurrence (SI Table 5). Thus,
the 14q13.3 focal amplification appears to confer more advanced
malignant properties to lung cancer cells. In contrast, wide DNA
copy number gain involving 14q13.3 did not correlate with
late-stage lung cancer or recurrence, reinforcing the basic
premise of this study that DNA copy number increases should be
considered in the context of whether they are focal or wide.
Discussion
Previous high-resolution oligonucleotide array-based CGH stud-
ies of human lung cancer have been reported (15, 30). Using
Fig. 2. Effects of overexpressing individually or combinatorially the 14q13.3
amplicon genes on the proliferation of premalignant lung epithelial cells. (A)
Colony formation of BEAS-2B retroviral transfectants stably expressing indi-
vidual genes (single transfectant) or pairwise combinations of the three
candidate driver genes (double transfectant). The assay was initiated by
plating 1,000 cells per well in six-well plates. After 12 days, cells were fixed and
stained with crystal violet. Representative pictures of experiments performed
in triplicate are shown. (B) The crystal violet stain in A was dissolved in 0.1%
SDS solution and quantified by absorbance at 595 nm according to Scragg and
Ferreira (20). V, vector only; N, NKX2-8; T, TTF1; P, PAX9; V-V, vector-vector;
T-P; TTF1-PAX9; N-P, NKX2-8-PAX9; T-N, TTF1-NKX2-8.
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bacterial artificial chromosome arrays, Garnis et al. (31) deter-
mined the whole-genome copy number alterations in 28 non-
SCLC cell lines. Here, we have used high-resolution genome
scanning by ROMA of 261 lung cancer samples to determine the
most frequently occurring high-amplitude focal amplicons in
lung cancer. The second most frequently recurring high-level
amplicon is at 14q13.3. We note that both Zhao et al. (30) and
Garnis et al. (31) also detected the 14q13.3 amplicon in their
studies. Although the high-level amplification of 14q13.3 ampli-
con as judged by ROMA in lung cancer is only 4.2%, by relaxing
the amplification cutoff from 1.5 (high level) to 1.2 (lower level),
our CGH data implicate 19% of analyzed samples are amplified
at 14q13.3. Collectively, these observations suggest that the
14q13.3 amplicon is a highly recurrent event in human lung
cancer.
A convergence of recent observations suggests a cell lineage
dependency (or lineage addiction) model of human cancer (32).
In the lineage addiction model, tumor cells are highly dependent
on the survival mechanisms that are built into the lineage
precursor cells during development, which might be genetically
altered to provide a survival advantage. In contrast to the well
publicized oncogene addiction model that invokes a tumor-
specific gain-of-function event (33), lineage dependency relies
on the deregulation of key developmental survival mechanisms
to promote tumorigenesis. Interestingly, given its essential func-
tion in lung development (34, 35) and restrictive expression in
lung tissue (36), TTF1 was speculated to be an appealing
candidate cell lineage-survival oncogene in lung cancer (32).
Very recently, Tanaka et al. (37) provided evidence that sus-
tained TTF1 expression may be crucial for a subset of lung AC.
However, in light of the findings of our study, we believe there
are several lines of evidence suggesting that TTF1 as well as
NKX28 and PAX9 are lung cell lineage addiction oncogenes. In
addition to lung cancer, by using the same ROMA platform of
array CGH, we have profiled other cancer types (see SI Table 7).
Other than the amplified lung cancer samples, the only samples
showing DNA gain at 14q13 were six breast and two colon cancer
DNAs. However, in each case, the DNA gain was extremely wide
(20 Mb), and it is thus unlikely that the 14q13.3 locus is the
specific target of amplification. Based on these observations and
other published CGH studies (reviewed in refs. 38 and 39), it
appears that the focal 14q13.3 amplicon takes place preferen-
tially in lung cancer, consistent with a lineage connection to the
underlining driver genes.
Classically, each amplicon is presumed to target one driver
gene for its functional advantage. However, data emerging from
recent studies suggest that multiple coamplified genes within a
given amplicon could be functionally relevant. Several reports in
the literature lend support to the thesis of ‘‘multiple driver
genes’’ per amplicon. Amplicons that have been shown func-
tionally involving multiple driver genes include the 11q22 am-
plicon in liver cancer (40), the HER2 amplicon (41), and the
8p11-12 amplicon (42) in breast cancer, the 3q26.2 amplicon in
ovarian cancer (43), and finally the 19q13 amplicon in pancreatic
cancer (44). Based on our findings, the focal point of this study,
14q13.3 amplicon, is very likely to also involve multiple coam-
plified driver genes. Functionally, both NKX2-8 and TTF1 were
able to enhance the tumorigenicity of a nonamplified lung SCC
cell line, establishing that both genes are capable of oncogenic
activity. Furthermore, substantial synergistic growth effects of
all pairwise combinations of the three genes was observed when
introduced into immortalized premalignant lung epithelial cells.
This surprising finding highlights the possibility that these can-
didate oncogenes functionally cooperate to promote lung cancer
cell growth.
Fig. 3. Continuous expression ofNKX2-8 and PAX9 is essential to the tumor maintenance of amplified SCC cells. (A) Western blot analysis indicates the absence
of Ttf1 protein expression in two lung SCC cell lines (H2170 and HCC15), as expected from the literature (21–24). Two additional SCC cell lines (EPLC-272H and
CHAGO-K-1) were also shown by immunoblotting to lack the expression of Ttf1 protein (data not shown). Analysis of the large-cell lung cancer cell line (H661)
was included as a positive control. Twenty micrograms of whole-cell extracts were loaded. The 14q13.3 amplicon status and tumor subtype are as indicated. (B
and D) Effective shRNAs (indicated by an asterisk) in knocking down the endogenous protein expression of NKX2-8 or PAX9 were identified by immunoblotting
of whole-cell extracts prepared from stable transfectants based in the amplified H2170 cells. Immunoblottings of -actin or tubulin were performed to control
for total amounts of proteins analyzed. (C and E) Stable H2170 transfectants expressing individual shRNAs ofNKX2-8 or PAX9were evaluated for tumorigenicity
in athymic nude mice. Approximately 24 h before injections, the mice were gamma-irradiated at 400 rad to minimize residual immune responses. Subsequently,
five million cells of individual transfectant populations were injected into a group of five athymic nude mice s.c., and these animals were observed weekly for
tumor formation. Tumor take rate was calculated as of the last weekly tumor measurement, and the averaged tumor size (y axis) was plotted against days after
injection (x axis).











In sum, we conclude that we have discovered an important
recurrent amplicon in lung cancer. The three genes affected by
this lesion are potentially novel lung oncogenes that cooperate
to promote lung cancer cell proliferation. Our findings have
strengthened the growing body of evidence that many amplifi-
cation events select multiple cooperating oncogenes. This has
important implications for the large functional genomic projects
aimed at identifying cancer-relevant genes. Large genome-scale
cDNA or RNAi screens that assay one gene at a time will not
uncover activities that rely on multiple collaborating genes. Only
through direct genomic analysis of human cancer will we be able
to discover these important interactions.
Materials and Methods
Primary Lung Tumors and Lung Cancer Cell Lines. Primary fresh-
frozen lung tumors were obtained from the Cooperative Human
Tissue Network (CHTN, Eastern Division, Philadelphia, PA)
and from the laboratory of M. Wigler at Cold Spring Harbor
Laboratory. Tumor samples, coded anonymously, were exam-
ined histologically to ensure at least 70%malignant tissue before
CGH study. The majority of cancer cell lines were acquired from
either American Type Culture Collection (Manassas, VA) or
Deutsche Sammlung von Mikroorganismen und Zellkulturen
(Braunschweig, Germany). Genomic DNA were prepared by
using the proteinase-K method with at least three rounds of
phenol/phenol-chloroform extraction to minimize protein con-
taminants (45). RNA of cell lines and tumors was prepared by
using Qiagen (Valencia, CA) RNeasy mini kit.
CGH and Gene Expression Profiling. CGH microarrays bearing
85,000 oligonucleotides designed to hybridize BglII restriction
fragments of human genome were custom synthesized by
Nimblegen Systems (Madison, WI) (13). The microarray hybrid-
ization was performed essentially as described (46). A more
detailed description is presented in SI Text.
QPCR, RNAi, and Cell Culture Assay. QPCR experiments to deter-
mine DNA copy number and RNA expression were conducted
essentially as described byMu et al. (47). The QPCR probes were
designed by using Primer Express 2.0 software (Applied Biosys-
tems, Foster City, CA), and the sequences are listed in SI Text.
shRNA selection and creation of stable shRNA transfectants
were as described (26, 27). The actual shRNA inserts cloned into
the pMLP retroviral expression vector (27) are listed in SI Text.
Retrovirus-mediated gene transfer was achieved with themurine
stem cell virus-based expression vectors (see SI Text).
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